Global biopharmaceutical giant Bristol Myers Squibb is focused on developing innovative medicines that address the unmet needs of patients with serious diseases. Clinical trials are key to the company's research and development (R&D) process. Teams internal to Bristol Myers Squibb conduct some of these studies, while external clinical research organizations (CROs) handle others. Either way, insurance is a prerequisite before any clinical trial can get under way.
"Clinical trial insurance protects participants, covering expenses in the event that a patient sustains injuries during the trial," explains Henry Huseby, director, corporate insurances. "The unique challenge for a global pharma company is that every country requires you to have clinical trial insurance, but no two countries are the same. The insurance you buy in Romania is completely different from what you buy in Australia."
Continue Reading for Free
Register and gain access to:
- Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
- Informative weekly newsletter featuring news, analysis, real-world cas studies, and other critical content
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
*May exclude premium content
Already have an account?
Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Meg Waters
Meg Waters is the editor in chief of Treasury & Risk. She is the former editor in chief of BPM Magazine and the former managing editor of Business Finance.
